Cipla enlarges US footprint

0
1477
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Indian pharmaceuticals manufacturer Cipla has agreed to purchase two US generics companies for US$550 million. Through its UK arm – Cipla EU – it will fork out US$500 million to take control of InvaGen Pharmaceuticals and US$50 million for Exelan Pharmaceuticals in an all-cash transaction. The deal will give Cipla a foothold in the US generics market through cardiovascular, anti-infective, diabetes and other generics.

The deal is one of the biggest overseas purchases by an Indian pharmaceutical player and is expected to close by the end of the year.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link